In the Claims

Claims 1-32 (cancelled)

Claim 33. (Previously presented) A method for enhancing optical purity of S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2- carboxylic acid L-arginine salt comprising, the steps of:

(a) suspending a partially optically impure mixture of 9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H, 5H-benzo[i,j] quinolizine-2-carboxylic acid in water and organic solvent selected from acetone or acetonitrile to form a suspension,

(b) adding an equimolar quantity of L-arginine to the suspension and heating the suspension to a temperature between about 40 to 70°C to obtain a clear solution,

(c) adding 2 to 3 times more of the organic solvent added in step (a),

(d) cooling the solution to 0 to 45°C, for 1 hr to 5 hr, to effect the crystallization;

(e) isolating the crystalline form of S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl -1-oxo-1H,5H-benzo[i,j]quinolizine-2- carboxylic acid L-arginine salt at below 35°C by filtration, and

(f) drying the crystalline form of S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine -2-carboxylic acid L-arginine salt.

Claims 34 - 46 (cancelled)

Claim 47. (Previously presented) The process according to claim 33, wherein the optically impure mixture of 9-fluoro-6,7-dihydro-8-(4- hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H, 5H-benzo [i, j]quinolizine-2-carboxylic acid comprises S-(-) to R-(+)-isomer of 9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1- yl)-5-methyl-1-oxo-1H, 5H-benzo[i, j]quinolizine-2-carboxylic acid in a ratio of from 70:30 to 97:3.

Claim 48. (Cancel)